• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Mayo Clinic, SandboxAQ Expand Collaboration to Advance AI Cardiac Diagnostics in Amyloidosis

by Fred Pennic 01/17/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Image by freepik

What You Should Know:

– Mayo Clinic is expanding its collaboration with SandboxAQ, a provider of artificial intelligence (AI) medical apps to explore the use of electrocardiography (ECG) and magnetocardiography (MCG) technologies for characterizing disease progression and treatment response in patients with amyloidosis.

– The expanded partnership highlights the potential of combining AI and advanced sensing technology to revolutionize cardiac diagnostics.

Improved Detection and Monitoring of Amyloidosis and Other Cardiac Conditions

Amyloidosis is a condition characterized by the buildup of abnormal protein deposits in organs and tissues, including the heart. Early diagnosis and accurate monitoring are crucial for effective management, but current tools often fall short in detecting subtle changes in cardiac function.

The expanded collaboration aims to address this challenge by integrating the established reliability of ECG with the cutting-edge sensitivity of MCG. MCG is a non-invasive technology that measures the magnetic fields generated by the heart’s electrical activity, providing a more detailed picture of cardiac function compared to ECG alone.

By combining these two modalities with SandboxAQ’s advanced AI algorithms, the partnership seeks to develop a novel diagnostic solution that offers deeper insights into the electrical and magnetic activity of the heart. This approach has the potential to:

  • Improve early detection of amyloidosis: Identify subtle changes in cardiac function that may be missed by traditional methods.
  • Enhance disease monitoring: Track disease progression and treatment response more accurately over time.
  • Enable personalized treatment: Guide clinical decision-making and optimize treatment strategies for individual patients.

“By uniting AQMed’s technical innovation with Mayo Clinic’s renowned research and clinical excellence, we aim to make a meaningful impact on the lives of amyloidosis patients across the globe in the near future,” said Kit Yee Au-Yeung, GM of SandboxAQ’s AQMed division.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Cardiac Monitoring, heart disease

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |